ClinicaliQ Trial Snapshot
- A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) — Active Not Recruiting • Phase III • NCT06081894.
- Aficamten improves symptoms and exercise ability in non-obstructive hypertrophic cardiomyopathy compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy. Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy Interventions: Aficamten, Placebo Lead Sponsor: Cytokinetics Planned Enrollment: 500 participants